Berberis aristata/Silybum marianumfixed combination on lipid profile and insulin secretion in dyslipidemic patients
- 6 August 2013
- journal article
- research article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 13 (11) , 1495-1506
Abstract
Background: Relatively large number of dietary supplements and nutraceuticals have been studied for their supposed or demonstrated ability to reduce cholesterolemia in humans. Objectives: The aim of this study was to evaluate the efficacy as antihypercholesterolemic and insulin-sensitizing agent of a combination of Berberis aristata/Silybum marianum extract (Berberol®) in a sample of dyslipidemic patients. A total of 102 dyslipidemic subjects were enrolled. After a 6 months run-in period of diet and physical activity, the patients were randomized to placebo or Berberis aristata/Silybum marianum extract 588 mg/105 mg, twice a day for 3 months. Berberis aristata/Silybum marianum and placebo were then interrupted for 2 months (washout period), and then restarted for further 3 months. Anthropometric and metabolic parameters were assessed; moreover, all patients underwent a glucagon stimulation test. Results: Berberis aristata/Silybum marianum reduced total cholesterol, triglycerides and low-density lipoprotein cholesterol and increased high-density lipoprotein cholesterol after 3 months from randomization and compared to placebo group. When Berberis aristata/Silybum marianum was interrupted, lipid profile worsened, and it improved again when nutraceutical combination was reintroduced. During the glucagon stimulation test, a higher increase of C-peptide levels and a lower increase in glycemia after the test with Berberis aristata/Silybum marianum compared to placebo, to baseline and to randomization were recorded. No patients had serious adverse events in both groups. Conclusion: Berberis aristata/Silybum marianum is effective and safe in improving lipid profile and insulin secretion in euglycemic dyslipidemic patients.Keywords
This publication has 30 references indexed in Scilit:
- Effects of berberine on lipid profile in subjects with low cardiovascular riskExpert Opinion on Biological Therapy, 2013
- High density lipoprotein and cardiovascular diseasesWorld Journal of Cardiology, 2013
- Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: Evaluation with euglycemic clamp and oral fat loadJournal of Clinical Lipidology, 2012
- High-density lipoprotein levels and risk of cardiovascular eventsJournal of Cardiovascular Medicine, 2012
- Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effectsExpert Opinion on Drug Safety, 2012
- Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trialsExpert Opinion on Biological Therapy, 2012
- Effects of n‐3 PUFA on insulin resistance after an oral fat loadEuropean Journal of Lipid Science and Technology, 2011
- Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE ModelAdvances in Preventive Medicine, 2011
- Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription?Mediterranean Journal of Nutrition and Metabolism, 2008
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final ReportCirculation, 2002